Stein, Eytan

Publications

Sort by

Co-Author Network

selected publications

Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response. Clinical lymphoma, myeloma & leukemia. 2019 Information Resource GET IT
Times cited: 4
Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. Leukemia research. 2019 Academic Article GET IT
Time to repeal and replace response criteria for acute myeloid leukemia?. Blood reviews. 2019 Information Resource GET IT
Times cited: 27
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2018 Academic Article GET IT
Times cited: 271
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 548
Widespread use of measurable residual disease in acute myeloid leukemia practice. Leukemia research. 2018 Academic Article GET IT
Times cited: 6
Minimal Residual Disease in Acute Myeloid Leukemia: Prognostication and Pitfalls. Journal of oncology practice. 2017 Article GET IT
Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 12
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Academic Article GET IT
Times cited: 1212
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. Cancer discovery. 2017 Academic Article GET IT
Times cited: 101
Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction. The oncologist. 2017 Academic Article GET IT
Times cited: 29
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. Acta haematologica. 2016 Academic Article GET IT
Times cited: 14
Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. Leukemia research. 2016 Academic Article GET IT
Times cited: 15
Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia. 2016 Academic Article GET IT
Times cited: 52
Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2016 Academic Article GET IT
Times cited: 7
Emerging therapeutic drugs for AML. Blood. 2015 Information Resource GET IT
Times cited: 163
IDH2 inhibition in AML: Finally progress?. Best practice & research. Clinical haematology. 2015 Information Resource GET IT
Times cited: 40
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. British journal of haematology. 2015 Academic Article GET IT
Times cited: 15
Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy. British journal of haematology. 2015 Academic Article GET IT
Times cited: 18
Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L. Current opinion in hematology. 2015 Information Resource GET IT
Times cited: 46
Searching the central nervous system for relapsed acute promyelocytic leukemia. Leukemia & lymphoma. 2013 Article GET IT
Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leukemia research. 2013 Academic Article GET IT
Times cited: 65
Persistent problems with persistent disease: minimal residual disease in acute myelogenous leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Article GET IT
Provocative pearls in diagnosing and treating acute promyelocytic leukemia. Oncology (Williston Park, N.Y.). 2012 Information Resource GET IT
Times cited: 6
Novel and emerging drugs for acute myeloid leukemia. Current cancer drug targets. 2012 Information Resource GET IT
Times cited: 13
Does arsenic trioxide impact fertility?. Leukemia & lymphoma. 2012 Article GET IT
Times cited: 2
Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology (Baltimore, Md.). 2012 Information Resource GET IT
Times cited: 46
Curing all patients with acute promyelocytic leukemia: are we there yet?. Hematology/oncology clinics of North America. 2011 Information Resource GET IT
Times cited: 18
The coagulopathy of acute promyelocytic leukaemia revisited. Best practice & research. Clinical haematology. 2009 Information Resource GET IT
Times cited: 104

more ...

less ...

Background

education and training

M.D., Northwestern University Medical School 2007
B.A., University of Pennsylvania 1995

Contact

full name

Eytan Stein

primary email

eys9002@med.cornell.edu

VIVO Weill Cornell Medical College

Eytan Stein Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email